Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/357229
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampMiotto, Noelle-
dc.contributor.authorunicampMendes, Leandro César-
dc.contributor.authorunicampZanaga, Letícia Pisoni-
dc.contributor.authorunicampLazarini, Mariana-
dc.contributor.authorunicampPedro, Marcelo Nardi-
dc.contributor.authorunicampGonçales Junior, Fernando Lopes-
dc.contributor.authorunicampStucchi, Raquel Silveira Bello-
dc.contributor.authorunicampVigani, Aline Gonzalez-
dc.typeArtigopt_BR
dc.titlePredictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohortpt_BR
dc.contributor.authorMiotto, Noelle-
dc.contributor.authorMendes, Leandro C.-
dc.contributor.authorZanaga, Letícia P.-
dc.contributor.authorGoncales, Eduardo S.L.-
dc.contributor.authorLazarini, Maria S.K.-
dc.contributor.authorPedro, Marcelo N.-
dc.contributor.authorGonçales, Fernando L. Jr-
dc.contributor.authorStucchi, Raquel S.B.-
dc.contributor.authorVigani, Aline G.-
dc.subjectHepatite Cpt_BR
dc.subjectCirrose hepáticapt_BR
dc.subjectAgentes antiviraispt_BR
dc.subject.otherlanguageHepatitis Cpt_BR
dc.subject.otherlanguageLiver cirrhosispt_BR
dc.subject.otherlanguageAntiviral agentspt_BR
dc.description.abstractThe aim of this study was to determine risk factors for premature treatment discontinuation among patients with hepatitis C and advanced fibrosis with advanced fibrosis treated with interferon (IFN)-free direct antiviral agents (DAA)-based therapy. We included all patients with chronic hepatitis C virus infection and advanced liver fibrosis in whom treatment was initiated with IFN-free DAA therapy at a university hospital from December 2015 through June 2016. We prospectively collected data from medical records using standardized questionnaires and evaluated them using Epi Info 7.1.2.0. The primary outcome was treatment interruption and associated factors. In total, 214 patients were included in this study; 180 patients were treated with sofosbuvir (SOF)+daclatasvir±ribavirin (RBV), 31 received SOF+simeprevir±RBV, and three were treated with SOF+RBV. Treatment discontinuation rate was 8.9% (19 patients) and cirrhotic decompensation was the main reason [8 (42.1%)]. Among patients with Child B or C cirrhosis (31), 10 (32.2%) prematurely interrupted treatment. The risk factors for treatment discontinuation in univariate analysis were older age (P=0.0252), higher comorbidity index (P=0.0078), higher model for end-stage liver disease (P<0.0001), higher fibrosis index based on the 4 factores (P=0.0122), and lower hemoglobin (P=0.0185) at baseline. Multivariate analysis showed that older age (odds ratio: 1.1, 95% confidence interval: 1.02–1.19) and higher model for end-stage liver disease (odds ratio: 1.27, 95% confidence interval: 1.03–1.56) were associated with premature treatment interruption. Older age and advanced liver disease were related to treatment interruption. Identification of risk factors associated with treatment discontinuation is important to recognize patients who should be followed up closely during treatment, ando those whom possibly may not benefit from immediate DAA treatment or should be followed up closely during treatment.pt_BR
dc.relation.ispartofEuropean journal of gastroenterology and hepatologypt_BR
dc.relation.ispartofabbreviationEur. j. gastroenterol. hepatol.pt_BR
dc.publisher.cityPhiladelphia, PApt_BR
dc.publisher.countryEstados Unidospt_BR
dc.publisherLippincott Williams & Wilkinspt_BR
dc.date.issued2017-
dc.date.monthofcirculationOct.pt_BR
dc.language.isoengpt_BR
dc.description.volume29pt_BR
dc.description.issuenumber10pt_BR
dc.description.firstpage1149pt_BR
dc.description.lastpage1154pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0954-691Xpt_BR
dc.identifier.eissn1473-5687pt_BR
dc.identifier.doi10.1097/MEG.0000000000000944pt_BR
dc.identifier.urlhttps://journals.lww.com/eurojgh/Fulltext/2017/10000/Predictors_of_early_discontinuation_of.7.aspxpt_BR
dc.date.available2021-03-05T19:19:03Z-
dc.date.accessioned2021-03-05T19:19:03Z-
dc.description.provenanceSubmitted by Bruna Maria Campos da Cunha (bcampos@unicamp.br) on 2021-03-05T19:19:03Z No. of bitstreams: 0. Added 1 bitstream(s) on 2021-08-31T19:55:30Z : No. of bitstreams: 1 000409958200007.pdf: 231746 bytes, checksum: 0525dd7d7d9e36fac95ca6f9f5f3a5f0 (MD5)en
dc.description.provenanceMade available in DSpace on 2021-03-05T19:19:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2017en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/357229-
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.departmentDepartamento de Clínica Médicapt_BR
dc.contributor.departmentsem informaçãopt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.contributor.unidadeCentro de Hematologia e Hemoterapiapt_BR
dc.subject.keywordDirect antiviral agentspt_BR
dc.subject.keywordHepatitis C treatmentpt_BR
dc.subject.keywordTreatment interruptionpt_BR
dc.identifier.source000409958200007pt_BR
dc.creator.orcid0000-0002-1172-8481pt_BR
dc.creator.orcidSem informaçãopt_BR
dc.creator.orcid0000-0002-9806-3899pt_BR
dc.creator.orcid0000-0002-5030-7583pt_BR
dc.creator.orcid0000-0002-8507-8987pt_BR
dc.creator.orcidSem informaçãopt_BR
dc.creator.orcid0000-0001-9536-6299pt_BR
dc.creator.orcid0000-0002-6897-3154pt_BR
dc.type.formArtigo originalpt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000409958200007.pdf226.31 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.